Masato Murakami, MD, PhD (he/him/his)

CMO
PeptiDream Inc., Japan

Masato Murakami, MD/PhD/MBA, Chief Medical Officer of PeptiDream Inc/PeptiAID.
I have worked for pharmaceutical company for over 15 years in R&D, especially in early clinical and translational development in not only Infection disease area but also Oncology disease area. Extensive knowledge of drug development in small weight molecule and biologics (especially Antibody Drug Conjugate)

Poster(s):

• (2141) Preclinical Evaluation of PA-001: A Novel, Potential Macrocyclic Peptide-Based Treatment for COVID-19 Which Binds to the S2 Subunit of SARS-CoV-2 Spike Protein
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2524) Safety and Pharmacokinetics of PA-001, a New Potential COVID-19 Drug That Targets the S2 Subunit of SARS-CoV-2 Spike Protein, in Healthy Subjects
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET